Latest / Neuro-Oncology: The Podcast

Neuro-Oncology Nugget: GT-20 Phase 1 Trial — Personalized Neoantigen DNA Vaccine for MGMT Unmethylated Glioblastoma
Host/Interviewee: ç, PhD Candidate, UT Health San Antonio
Description: Shahad Abdulsahib discusses the GT-20 phase 1 clinical trial evaluating GNOS-PV01, a personalized multivalent neoantigen DNA vaccine administered following surgical resection and radiation in patients with MGMT unmethylated glioblastoma, with findings published in Nature Cancer on May 12th, 2026.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.